OAM
TXG icon

Oppenheimer Asset Management’s 10x Genomics TXG Stock Holding History

Oppenheimer Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,700
Closed -$205K – 1221
2022
Q1 		$205K Buy
2,700
+1,292
+92% +$113K ﹤0.01% 1127
2021
Q4 		$210K Buy
+1,408
New +$216K ﹤0.01% 1166

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Oppenheimer Asset Management's TXG Position: Q2 2022 in Review

Oppenheimer Asset Management sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 2,700 shares — an estimated $205K sold.

Oppenheimer Asset Management first reported a position in TXG in Q4 2021 and held it in 2 quarters. The position peaked at $210K in Q4 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

  • Oppenheimer Asset Management reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
  • Oppenheimer Asset Management sold 2,700 10x Genomics shares in Q2 2022, an estimated $205K.
  • Oppenheimer Asset Management first reported a position in 10x Genomics in Q4 2021 and held it in 2 quarters.
  • Oppenheimer Asset Management's 10x Genomics position peaked at $210K in Q4 2021.
  • 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Oppenheimer Asset Management's 13F filing for Q2 2022, filed 8 Aug 2022.